UBI Pharma obtains a US patent certificate for the "Single-Chain Immunoglobulin Fusion Protein Technology Platform."

Our company's developed Single-Chain Immunoglobulin Fusion Protein Technology Platform has been approved by the United States Patent and Trademark Office (US Patent No.: US 11,820,807 B2).

This technology has obtained patents in China, Japan, Taiwan, India, Australia, Malaysia, and Hong Kong, with pending reviews in Korea and Singapore.

This technology is being applied in the ongoing development of our products, UB-551 and UB-853.